89bio EBIT

The latest EBIT for ETNB is $-460M as of June 2025. That compares with $-190M in the prior-year period — down 139.0% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside 89bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, ETNB's EBIT moved from $-190M to $-460M — a 139.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 89bio's operating scale or balance-sheet position.

Against Healthcare companies, ETNB currently prints $-460M for EBIT, while the sector average sits near $22B. That is roughly 102.0% below the sector mean. Large gaps often invite a closer look at 89bio's growth, margins, and balance sheet.

A EBIT figure of $-460M for ETNB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting ETNB's EBIT ($-460M), review year-over-year change from $-190M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.